TCTR20161115001招募中4 期
Bioequivalence Study of 5 mg Nebivolol Tablets in Healthy Thai Volunteers under Fasting Conditions
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Healthy Thai male or female volunteers aged between 18 and 55 years.
- •2.The Body Mass Index (BMI) ranges from 18 to 25 kg/m2.
- •3.Determined healthy by medical history, physical examination and vital signs
- •4.The results of the clinical laboratory tests are within clinically acceptance limits i.e., blood urea nitrogen (BUN), serum creatinine, AST, ALT, total bilirubin, alkaline phosphatase, blood potassium, sodium, calcium, chloride, fasting blood sugar and hematology examinations including differential blood counts and HBsAg test. Some of the clinical laboratory values that out of the normal range will be carefully considered by clinical investigator.
- •5.Negative pregnancy test for female volunteers and effective contraceptive must be used at least 14 days prior to the study initiation until 14 days after the last drug administration and not breast-feeding women.
- •6.Male volunteers who are surgically sterile or agree to use an effective contraception throughout the study and until the completion of the study.
- •7.Willing to participate in the study and signed the informed consent form.
排除标准
- •1.History or evidence of allergy or hypersensitivity to nebivolol hydrochloride or any of the excipients of this product or any related drugs.
- •2.History or evidence of allergy or hypersensitivity to heparin.
- •3.History or evidence of hypertension (systolic BP 140 mmHg, diastolic BP 90 mmHg) or hypotension (systolic BP <90 mmHg, diastolic BP <60 mmHg).
- •4.History or evidence of gastrointestinal, hepatic, renal, cardiovascular, hemato-logical disease or allergic disease or bronchial asthma or any disease that may affect the bioavailability of drug.
- •5.ECG results show malignant arrhythmia, or QTc >450 msec, a QRS interval >120 msec or with an abnormality considered clinically significant at screening or HR <40 bpm, or HR > 110 bpm. If QTc exceeds 450 msec, or QRS exceeds 120 msec, two more ECG tests must be performed and the average of the three QTc or QRS values should be used to determine the subject’s eligibility.
- •6.History of chronic or debilitating diseases.
- •7.History or evidence of CYP2D6 poor metabolizer.
- •8.Positive HBsAg tests.
- •9.History of alcoholism or drug abuse.
- •10.Positive urine drug abuse tests (Benzodiazepines, Methamphetamine and Opi-ates).
- •11.History of regular alcohol consumption (more than 1 time a week) or alcohol consumption within 7 days prior to the study drug administration and until the completion of the study.
- •12.History of smoking more than 10 cigarettes/day, or moderate smokers (less than 10 cigarettes/day) and could not quit at least 7 days prior to the study drug administration and until the completion of the study.
- •13.Tea/coffee or caffeine- or xanthine-containing beverage consumption within 7 days prior to the study drug administration and until the completion of the study.
- •14.Grapefruit juice or grapefruit-containing products consumption within 7 days prior to the study drug administration and until the completion of the study.
- •15.Use of any prescription drugs or over-the-counter (OTC) drugs or herbal medi-cines within 30 days or vitamins or food supplements within 14 days prior to the study drug administration or use hormonal methods of contraception with-in 28 days (discontinuation for at least 6 months is required for Depo-Provera use) prior to receiving the first dose of the study medication and until the com-pletion of the study.
- •16.Blood donation or blood loss over 350 mL within 90 days preceding the admis-sion into the study.
- •17.Participation in any clinical studies within 90 days preceding the admission into this study.
研究者
相似试验
尚未招募
1 期
Nebivolol Tablets 5 mg Relative to Nebilet Tablets 5 mgHealthy SubjectsNCT06248099Bio-innova Co., Ltd46
进行中（未招募）
1 期
Effects Of The Administration Of Nebivolol Versus Carvedilol On Microcirculatory Endothelial Function, Arterial Stiffness And Wave Reflection In Healthy Volunteers” (NeCaMic-study) - NeCaMicMicrocirculatory Endothelial Function, Arterial Stiffness And Wave ReflectionEUCTR2009-014643-36-BEMENARINI Benelux NV/SA
尚未招募
1 期
A Bioequivalence Study of Two Formulations of 5 mg Montelukast Chewable Tablets in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai VolunteersTCTR20210720012Siriraj Institute of Clinical Research (SICRES)28
进行中（未招募）
1 期
A trial to compare the effects of nebivolol versus atenolol on various cardiovascular measurements including insulin sensitivity - Nebivolol trialHypertensionEUCTR2005-001214-40-GBImperial College London50
招募中
不适用
In-vivo Bioequivalence Test of Ibuprofen tablet 800 mg Mofid Pharma with brand drug (BRUFEN® ER. 800 mg Tab, Mylan, Germany)Bio equivalence test.IRCT20200105046010N67Teb Mofid Nikan Pharmaceutical Co.24